Gefitinib may be effective to treat esophageal cancer in some patients
the ONA take:
According to new research published in The Lancet Oncology, gefitinib, a drug already used to treat lung cancer, may be effective to treat esophageal cancer in a small subgroup of patients. In the Cancer Oesophagus Gefitinib study, researchers tested gefitinib in patients with esophageal cancer who had progressed after chemotherapy.
The study showed that gefitinib had minimal impact on most patients and only increased survival rates by a small amount; however, the drug did drastically improve the quality of life, survival duration, and symptom control in about 15% of patients. The main adverse effect was diarrhea.
Russell Petty, PhD, of the University of Aberdeen in Aberdeen, Scotland and senior researcher of the study said that the patients who improved on gefitinib did so within a few weeks of initiating therapy and some patients had disease control for almost 2 years. Dr. Petty notes that not all patients with esophageal cancer should be offered gefitinib and that there is a need for a test to screen whether a patient would improve on gefitinib.
Gefitinib (Iressa), a tyrosine kinase inhibitor, was approved in 2003 by the U.S. Food and Drug Administration to treat advanced EGFR mutation-positive non-small cell lung cancer.
Findings of a trial could lead to a new treatment approach for oesophageal cancer.
The University of Aberdeen was involved in a UK wide study to see if the drug gefitinib - already used in lung cancer - could help treat oesophageal cancer.
The Cancer Oesophagus Gefitinib trial was the first study conducted in oesophageal cancer patients whose disease had progressed after chemotherapy.
Sign Up for Free e-newsletters
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- USPSTF Still Recommends Against Pancreatic Cancer Screening
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Shifting Dynamics of Social Support After a Cancer Diagnosis
- Survey Demonstrates Implicit Bias Toward Cervical Cancer Diagnoses Among Nurses, Women
- Use of Watchful Waiting Up for Low-Risk Localized Prostate Cancer
- Sharing Personal Contact Information With Patients
- Country-Specific Norms Created for Cancer-Related Quality of Life
- Nurse-Led vs Oncologist-Led Breast Cancer Follow-up Program: Early Feasibility Results of an Ongoing Study
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|